Table 2.
Estimated incidence of cytomegalovirus disease during the first 12 mo after liver transplantation
Use of anti-cytomegalovirus prophylaxis |
||
Yes1 (%) | No (%) | |
CMV D+/R- | 12-30 | 44-65 |
CMV D+/R+ | 2.70 | 18.20 |
CMV D-/R+ | 3.90 | 7.90 |
CMV D-/R- | 0.00 | 0.00 |
All patients | 4.80 | 18-29 |
D: donor; R: recipient; CMV: cytomegalovirus.
Most cases occur as delayed-onset CMV disease. CMV disease occurs rarely during prophylaxis with oral valganciclovir. Data adapted from references [4,5,77].